Tumor regression grades, K-RAS mutational profile and c-MET in colorectal liver metastases

Pathol Res Pract. 2017 Aug;213(8):1002-1009. doi: 10.1016/j.prp.2017.04.013. Epub 2017 Apr 21.

Abstract

Introduction: Recently TRG, necrosis grade and the rate of viable cancer cells of colorectal liver metastases were correlated with the response to chemotherapy treatments, whereas K-RAS mutations and c-MET over-expression were correlated with the prognosis.

Methods: 58 resection specimens were assessed for regression grades. Patients undergone neo-adjuvant treatments were compared to patients who underwent therapy exclusively adjuvantly. We investigated the K-RAS mutational profile, the c-MET over-expression along with patients' survivals curves.

Results: Patients undergone neo-adjuvant treatment presented significant higher fibrosis rates and lower rates of viable cells. 36.7% of the patients had a K-RAS mutation and the 26.7% presented c-MET over-expression, but these features did not correlate with patients' clinical/pathological data. Survival analysis documented that K-RAS WT patients presenting c-MET over-expression had worse outcomes.

Conclusion: Fibrosis and the rate of viable cells significantly correlate with the response to chemotherapy treatments. c-MET is a promising marker in K-RAS WT patients.

Keywords: C-MET; Colorectal cancer; K-RAS; Liver metastasis.

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / secondary*
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / pathology*
  • Colorectal Neoplasms / therapy
  • DNA Mutational Analysis
  • Disease-Free Survival
  • Female
  • Fibrosis / pathology
  • Humans
  • Kaplan-Meier Estimate
  • Liver Neoplasms / genetics
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Proto-Oncogene Proteins c-met / biosynthesis*
  • Proto-Oncogene Proteins p21(ras) / genetics*

Substances

  • Biomarkers, Tumor
  • KRAS protein, human
  • MET protein, human
  • Proto-Oncogene Proteins c-met
  • Proto-Oncogene Proteins p21(ras)